» Articles » PMID: 38695959

Lung Cancer-specific Symptoms and Fear of Cancer Recurrence Among Recurrence-free Non-small Cell Lung Cancer Survivors

Overview
Specialties Critical Care
Oncology
Date 2024 May 2
PMID 38695959
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Lung cancer survivors have more psychosocial problems, including depression and anxiety disorder, than other cancer survivors. Lung cancer-specific symptoms, such as cough, dyspnea, or pain in chest, might increase FCR among survivors. We aimed to evaluate the association between lung cancer-specific symptoms and FCR among recurrence-free non-small cell lung cancer (NSCLC) survivors.

Methods: This is a cross-sectional study. Recurrence-free NSCLC survivors were recruited from January to October 2020 at a tertiary hospital in Seoul, Korea. We measured FCR using the Korean version of FCRI-SF and categorized them into three groups: non-clinical FCR (nFCR, < 13), subclinical FCR (sFCR, 13 to 21), and clinical FCR (cFCR, ≥ 22). Lung cancer-specific symptoms were measured using the Korean version of EORTC QLQ-LC13 and EORTC QLQ-C30.

Results: A total of 727 survivors were enrolled. One-third (30.8%) of survivors reported sFCR, and 19.7% had cFCR. In a multivariate analysis, survivors with severe pain in chest were 4.7 times (95% CI: 2.4-9.0) more likely to experience cFCR compared to those without it. Mild dyspnea (OR 1.7, 95% CI: 1.1-2.7) and mild dysphagia (OR 2.4, 95% CI: 1.3-4.4) were associated with cFCR. Survivors with sFCR (Coef. - 6.3, 95% CI: - 9.8, - 2.8) and cFCR (Coef. - 11.3, 95% CI: - 15.5, - 7.2) had poorer quality of life compared to survivors with nFCR.

Conclusion: NSCLC survivors were experiencing lung cancer-specific symptoms even a few years after treatment, which were associated with cFCR, resulting in poor HRQoL. It is necessary to develop a lung cancer-specific symptom checklist and use it during even long-term surveillance.

References
1.
Ganti A, Klein A, Cotarla I, Seal B, Chou E . Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021; 7(12):1824-1832. PMC: 8532041. DOI: 10.1001/jamaoncol.2021.4932. View

2.
Baker F, Denniston M, Smith T, West M . Adult cancer survivors: how are they faring?. Cancer. 2005; 104(11 Suppl):2565-76. DOI: 10.1002/cncr.21488. View

3.
Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S . Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013; 7(3):300-22. DOI: 10.1007/s11764-013-0272-z. View

4.
Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S . The prevalence of psychological distress by cancer site. Psychooncology. 2001; 10(1):19-28. DOI: 10.1002/1099-1611(200101/02)10:1<19::aid-pon501>3.0.co;2-6. View

5.
Luigjes-Huizer Y, Tauber N, Humphris G, Kasparian N, Lam W, Lebel S . What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. Psychooncology. 2022; 31(6):879-892. PMC: 9321869. DOI: 10.1002/pon.5921. View